Lipidomics in Obesity-Related Asthma (LORA)

E
Erick Forno

Primary Investigator

Enrolling By Invitation
8 years - 21 years
All
Phase N/A
100 participants needed
1 Location

Brief description of study

What is the purpose of this study?

The purpose of this research is to learn more about how the levels of different lipids affect kids with asthma and obesity. We're especially interested in how it affects kids with certain characteristics or types of asthma. In the long term, we hope this will help us understand if taking algae oil (high in certain types of lipids) might help some kids with asthma control their symptoms and reduce inflammation in their lungs.

THIS STUDY IS ENROLLING BY INVITATION ONLY - Screening will occur in collaboration with the treating clinical providers, who will identify potentially eligible subjects from the Pulmonary and Allergy clinics, the Riley ED, and the inpatient Pulmonary team. A member of the research study team will then proceed to obtain parental informed consent; assent will also be obtained from all children >8 years old. Subjects might also be recruited using word of mouth and/or siblings of participants. We might also recruit subjects from IU North (same clinics and departments), but all study visits will take place at Riley.

Detailed description of study

What will happen during the study?

  • We will test the associations between plasma lipidomic profiles.
  • Participants will complete up to 2 study visits over 3 months
  • Study visits will take place at Riley Hospital for Children in the Children's Clinical Research Center (CCRC) and/or the Pulmonary Function Testing (PFT) lab.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Asthma, Riley
  • Age: 8 years - 21 years
  • Gender: All

Inclusion criteria:
•    Age ≥8 to <21 years (i.e., 8.00-20.99 years)
•    Diagnosis of persistent asthma (defined as prescription of ICS for ≥6 months of the past year)
•    At least 1 severe exacerbation in the past year (defined per ATS/ERS criteria as a hospitalization, ED visit, or ≥3 days of systemic steroids for asthma)
•    Stable ICS dose for ≥4 weeks prior to enrollment
•    Ability to perform high-quality spirometry per ATS guidelines
•    BMI ≥5 to <85th percentile (HWA) or ≥85th percentile (ORA)

Exclusion criteria:
•    Asthma that requires chronic systemic steroids.
•    Any of the following in the past 4 weeks**:
o    Systemic or nasal steroids
o    Acute lower respiratory illness
o    Acute sinusitis requiring antibiotics
o    Reported smoking, vaping, or e-cigarette use
o    Concurrent enrollment in any interventional studies
o    DHA, -3, or other essential fatty acid dietary supplements
•    Other chronic respiratory diseases (e.g., cystic fibrosis, bronchopulmonary dysplasia).
•    Significant comorbidities that may affect participant safety or interfere with study outcomes.
•    Low BMI (< 5th percentile).

Updated on 21 Mar 2025. Study ID: PPUL-IIR-LORA, 26169
Please visit our main page to search for other studies you may be interested in. If you need help finding a study or have any questions, please contact us at inhealth@iu.edu

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center